Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing signs and symptoms of participants with active rheumatoid arthritis (RA) with methotrexate (MTX) therapy.


Options:
A: Arm Label: Part A, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part A, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 1; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 2; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Methotrexate | Arm Label: Part B, Group 3; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 100 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 4; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 50 mg, Drug: Placebo, Drug: Methotrexate | Arm Label: Part B, Group 5; Type: EXPERIMENTAL; Interventions: Drug: CNTO 136 25 mg, Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 136 100 mg; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3 | Intervention Type: DRUG; Name: CNTO 136 50 mg; Assigned to Arm(s): Part B, Group 4 | Intervention Type: DRUG; Name: CNTO 136 25 mg; Assigned to Arm(s): Part B, Group 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 3, Part B, Group 4, Part B, Group 5 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A, Group 1, Part A, Group 2, Part B, Group 1, Part B, Group 2, Part B, Group 3, Part B, Group 4, Part B, Group 5
B: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Eribulin mesylate 1.4 mg/m^2 intravenous | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV | Intervention Type: DRUG; Name: Eribulin mesylate 1.4 mg/m^2 intravenous; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV; Assigned to Arm(s): Arm B
D: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Arm Label: Regimen B; Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: ifosfamide, Drug: vincristine sulfate, Procedure: adjuvant therapy, Procedure: conventional surgery, Procedure: neoadjuvant therapy, Radiation: brachytherapy, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: brachytherapy; Assigned to Arm(s): Regimen A, Regimen B | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Regimen A, Regimen B

Answer: A